Supreme Court Directs Union to Form Committee on Pharma Regulations
The Supreme Court has mandated the formation of a committee to recommend regulations aimed at curbing unethical pharmaceutical marketing practices.
The Supreme Court ordered the Union of India to create a committee to address unethical marketing by pharmaceutical companies.
The committee's recommendations will be considered in a hearing scheduled for January 29.
The move follows concerns about the enforcement of existing marketing codes and the need for statutory regulations.
In a significant development, the Supreme Court of India has instructed the Union government to establish a committee tasked with recommending regulations to mitigate unethical marketing practices by pharmaceutical companies. This directive was issued during a hearing on October 8, 2026, where the Court emphasized the necessity of addressing the interactions between healthcare professionals and pharmaceutical firms that may compromise ethical standards.
The bench, comprising Justice Vikram Nath and Justice Sandeep Mehta, highlighted the importance of the committee's role in evaluating various suggestions and representations regarding pharmaceutical marketing. The Court has scheduled a follow-up hearing for January 29, 2027, to review the compliance affidavit from the Union, ensuring that the recommendations are taken seriously and acted upon.
This order stems from a petition advocating for statutory regulations to oversee pharmaceutical marketing practices. During the proceedings, Solicitor General Tushar Mehta indicated that the Union government is prepared to form a three-member committee to assess the necessity of a legal framework to regulate unethical practices in the industry. This commitment reflects a growing recognition of the need for oversight in pharmaceutical marketing.
Historically, the Court has raised questions about the effectiveness of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), established in 2024. Concerns were voiced regarding the enforcement mechanisms of the UCPMP and whether the government intended to provide statutory backing to the Code. The Court noted that without government oversight, the mandatory nature of the Code could become largely ineffective, leading to a voluntary compliance scenario that undermines its purpose.
The implications of this directive are substantial for the healthcare sector in India. By potentially instituting stricter regulations, the committee could help restore trust in the doctor-patient relationship and ensure that medical decisions are made based on patient welfare rather than pharmaceutical incentives. As the situation develops, stakeholders in the healthcare and pharmaceutical industries will be closely monitoring the outcomes of the committee's recommendations and the government's response in the upcoming months.
